as lockdown is lifted across the UK and Ireland, what could happen in paediatric emergency departments and hospitals this summer? a 🧵1/n
firstly, some context

in the first year of the pandemic, there were 5,336 hospital admissions associated with a positive SARS-CoV-2 test in children in England 2/n
but ...

in a typical year in England, there are ~36,000 admissions for bronchiolitis (mainly caused by Respiratory Syncytial Virus, RSV) in infants under the age of 1 thorax.bmj.com/content/75/3/2… 3/n
the pandemic saw an almost total disappearance of RSV across the UK gov.uk/government/sta… @PHE_uk 4/n
this was reflected in emergency department attendances for bronchiolitis across Scotland

in contrast to a usual winter peak, there were very few attendances, most likely representing ongoing rhinovirus circulation (@P_H_S_Official data) 5/n
much of the Southern Hemisphere saw a similar pattern

but what happened when lockdown was released?

in Western Australia the peak was larger than the normal winter peak academic.oup.com/cid/advance-ar… 6/n
in France, where schools have remained open throughout the winter and into spring, there is an unusual pattern to this year's epidemic, with a delayed start, and it isn't clear yet whether the peak has been reached santepubliquefrance.fr/maladies-et-tr… @SantePubliqueFr 7/n
what will happen in the UK?

very hard to predict & only a prospective study, collecting and releasing data in real time will allow us to see what is happening and act on this information

which is exactly what BronchStart @PERUKItweep sets out to do medrxiv.org/content/10.110… 8/n
some scenarios:

1. A larger unexposed cohort than usual with less maternal protection through recent RSV exposure, leads to larger peak than usual

2. Ongoing restrictions mean that we see a smaller peak, with rebound peak this autumn/winter when restrictions fully released 9/n
will RSV spread in its usual pattern (seeding through the metropolitan centres of London and Manchester thorax.bmj.com/content/75/3/2… @ThoraxBMJ ) or in a slower wave from France/Belgium northwards? 10/n
will we see an initial peak of rhinovirus bronchiolitis as restrictions are eased, followed by a delayed RSV peak? 11/n
all open questions, and in my opinion much more of a reason to worry about our summer holidays than vaccine passports

we need this information to understand how infants and children will present to EDs, guide decisions on palivizumab, and inform PICU service planning 12/n
we welcome comments on the study pre-protocol medrxiv.org/content/10.110… & participation of your emergency department through the PERUKI network

we thank all the people who have contributed towards the design of this study so far 13/n
and hope that this study, and others like it, will contribute towards the introduction of an effective RSV vaccine path.org/resources/rsv-… END

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Thomas Christie Williams

Thomas Christie Williams Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Williams_T_C

20 Feb
really excellent editorial @NEJM by @PerriKlass & @AdamRatnerMD on key issues surrounding vaccination of children against SARS-CoV-2 nejm.org/doi/full/10.10… 1/n
firstly: why should we vaccinate?
-to protect children, who can (rarely) develop severe disease, require hospitalisation, and (very rarely) die
-to protect vulnerable individuals who have contact with children
-to achieve herd immunity: 21% of UK population aged under 18 2/n
secondly, what do we need to vaccinate children?
-a vaccine that robustly protects against severe disease AND prevents transmission
-robust safety data, including paediatric-focused studies & post-licensure monitoring for potential rare outcomes like vaccine-associated MIS-C 3/n
Read 7 tweets
30 Jan
what a difference a month makes in a pandemic

Dec '20: lab studies show potential for SARS-CoV-2 mutations to impact antibody neutralisation

Jan '21: clinical trials @Novavax & @JNJGlobalHealth show 501Y.V2 appears to impact vaccine effectiveness, confirming predictions 🧵1/n
interested in the science underlying this?

if so my Comment with Wendy Burgers @virusmonologues is out today @LancetRespirMed thelancet.com/journals/lanre…

thankyou to @jbloom_lab for insightful comments on the piece 2/n
first important message is to highlight we are in incredibly fortunate position with SARS-CoV-2 vaccines

multiplicity of approaches to choose from (mRNA, Spike protein, adenovirus vector)

all of which show efficacy >50% even with the 501Y.V2 variant virological.org/t/mutations-ar… 3/n
Read 17 tweets
29 Jan
nice piece on the professional cycling landscape for the year ahead by @jeremycwhittle

do "athletes merit preferential treatment because of the cultural importance of sport to public mental health and wellbeing"?

and should they get priority in the vaccination queue 1/4
to allow sporting events to take place this summer?

Israel Start-Up Nation, a cycling team, already in "close talks with the Israeli Ministry of Health to assess whether, if there are vaccines available after the main programme takes place, the team can be allocated some.” 2/4
and if athletes merit preferential treatment, should other cultural figures (actors, musicians) get preferential treatment too?

I would argue not, but interested to see what @Twitter thinks 3/4
Read 5 tweets
28 Jan
new results just released by @Novavax for their UK and South African SARS-CoV-2 vaccine trials ir.novavax.com/news-releases/…

NVX-CoV2373 contains a recombinant Spike glycoprotein maintained in prefusion conformation with 2 proline substitutions nature.com/articles/s4146… 1/n
the UK arm enrolled more than 15,000 participants aged 18-84 with a primary endpoint of PCR confirmed symptomatic COVID-19

62 cases were observed overall, 56 in the placebo group and 6 in the NVX-CoV2373 group, giving an efficacy of 89.3% 2/n
the researchers also carried out a post-hoc analysis looking at efficacy for particular strains

they estimated an efficacy of 95.6% against the original COVID-19 strain and 85.6% against the UK variant strain B.1.1.7 3/n
Read 10 tweets
20 Jan
the data we've all been waiting for

is 501Y.V2 is less susceptible to neutralisation by convalescent sera than the original SARS-CoV-2 D614G lineage seen in South Africa?

short answer: yes 1/5

biorxiv.org/content/10.110…
panel a is 3 pie charts, sera from 44 patients

left pie chart shows neutralisation of original D614G variant by convalescent sera: dark blue= high neutralisation titres, and light blue = lower titres 2/5
right pie chart shows neutralisation of 501Y.V2 variant by same convalescent sera samples: red means loss of neutralising activity (red/black in columns below)

this loss is seen in 21/44 (48%) of total patient samples; only 3 samples retain high neutralising activity 3/5
Read 5 tweets
16 Jan
our study on the indirect effects of the COVID-19 pandemic on children now out @ADC_BMJ adc.bmj.com/content/early/…

many positives, in terms of our findings and how the paper came together

but also raises serious considerations for clinicians, researchers and government 🧵 1/n
first of all, the findings

at the start of the pandemic, we were concerned that radical shake-ups to health-care seeking behaviour and provision

might lead to delayed presentations & higher risk of injuries, accidental & non-accidental

& increased harm to children 2/n
(a reminder of the timeline for the first few months of the pandemic in Scotland) 3/n
Read 22 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!